Tandem Diabetes announces preliminary FY2022 results and FY2023 guidance; no specific figures disclosed in filing text

TANDEM DIABETES CARE INC

2022-FY EPS reported -$1.47 revenue$801,217,000

Press release contains unaudited preliminary Q4 and full-year 2022 results.
Results are preliminary and subject to adjustment; final audited results will be in the 10-K.
Company also provided preliminary financial guidance for the full year ending December 31, 2023.
Exhibit 99.1 text was not included in the provided filing, so specific numbers are unavailable.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TANDEM DIABETES CARE INC updated its the quarter and full year ended December 31, 2022 guidance (initiated).

Period: the quarter and full year ended December 31, 2022
Guidance: initiated
Result: preliminary results

Exact text from the filing

On January 10, 2023 , the Company issued a press release announcing its unaudited, preliminary financial results for the quarter and full year ended December 31, 2022, as well as its preliminary financial guidance for the full year ending December 31, 2023.

View on SEC.gov

Browse all earnings releases →

TANDEM DIABETES CARE INC filing history →

Source: SEC EDGAR

accession 0001438133-23-000005

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.